Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa-Reference-Cited by-同舟云学术

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa

Published:2020-03 Issue: Volume:20 Page:100290
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Mohr-Holland Erika,Reuter Anja,Furin Jennifer,Garcia-Prats Anthony,De Azevedo Virginia,Mudaly Vanessa,Kock Yulene,Trivino-Duran Laura,Isaakidis Petros,Hughes Jennifer

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Drug-resistant tuberculosis : will grand promises fail children and adolescents?;Furin;Lancet Child Adolesc Heal,2018

2. It's time to end drug-resistant tuberculosis;Case Action,2019

3. Tackling drug-resistant infections globally: final report and recommendations;Rev Antimicrob Resist,2016

4. Outcomes in adolescents undergoing treatment for drug-resistant tuberculosis in Cape Town, South Africa, 2008–2013;Moyo;Arch Pediatr Infect Dis,2014

5. Our future : a lancet commission on adolescent health and wellbeing;Patton;Lancet Comm,2016

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug‐Resistant and Extensively Drug‐Resistant Mycobacterium tuberculosis;Journal of Clinical Laboratory Analysis;2024-08

2. Bedaquiline and delamanid treatment outcomes among patients with drug-resistant tuberculosis: a systematic review and meta-analysis;Minerva Respiratory Medicine;2024-03

3. Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children;Frontiers in Cellular and Infection Microbiology;2023-06-13

4. Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now;Cureus;2023-02-18

5. Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB;The International Journal of Tuberculosis and Lung Disease;2023-01-01